Eosinophilic Fasciitis – Report of Three Cases and Review of the Literature

  • Uwe Wollina Städtisches Klinikum Dresden, Department of Dermatology and Allergology, Dresden, Germany
  • Gesina Hansel Städtisches Klinikum Dresden, Department of Dermatology and Allergology, Dresden, Germany
  • Jacqueline Schönlebe Institute of Pathology "Georg Schmorl", Städtisches Klinikum Dresden, Academic Teaching Hospital, Dresden, Germany
  • Birgit Heinig Center of Physical and Rehabilitative Medicine, Städtisches Klinikum Dresden, Academic Teaching Hospital, Dresden, Germany
  • Ivanka Temelkova Onkoderma - Clinic for Dermatology, Venereology and Dermatologic Surgery, General Skobelev 26, 1606, Sofia, Bulgaria
  • Georgi Tchernev Onkoderma - Clinic for Dermatology, Venereology and Dermatologic Surgery, General Skobelev 26, 1606, Sofia, Bulgaria
  • Aleksandra Vojvodic Department of Dermatology and Venereology, Military Medical Academy of Belgrade, Belgrade, Serbia
  • Torello Lotti University of Rome Guglielmo Marconi Rome, Italy
Keywords: Eosinophilic fasciitis, Fibrotic disorders, Scleroderma, Treatment, Corticosteroids, Methotrexate

Abstract

BACKGROUND: Eosinophilic fasciitis is a rare fibrosing disorder of muscle fascia with rapid onset of erythema, induration, oedema and tenderness affecting extremities bilaterally.

CASE REPORT: We report three cases of eosinophilic fasciitis in 3 females aged 64, 65 and 73 years, in two of them in association with morphea. They fulfilled the proposed diagnostic criteria. Associated malignancies could be excluded in all of them. They were treated by systemic corticosteroids. In the two females with associated morphea higher prednisolone dosages and a combination with methotrexate was necessary.

CONCLUSIONS: Eosinophilic fasciitis is a differential diagnosis of systemic scleroderma. Response to treatment is often delayed. Systemic corticosteroids are the first line therapy. Patients with associated morphea need combined drug therapy, in our patients with methotrexate. There is no close correlation between laboratory signs of inflammation and clinical response to treatment.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Plum Analytics Artifact Widget Block

References

Shulman LE. Diffuse fasciitis with hypergammaglobulinemia and eosinophilia: a new syndrome? J Rheumatol. 1974; 1(1):46.

Shulman LE. Diffuse fasciitis with eosinophilia: a new syndrome? Trans Assoc Am Physicians. 1975; 88:70-86.

Wright NA, Mazori DR, Patel M, Merola JF, Femia AN, Vleugels RA. Epidemiology and Treatment of Eosinophilic Fasciitis: An Analysis of 63 Patients From 3 Tertiary Care Centers. JAMA Dermatol. 2016; 152(1):97-9. https://doi.org/10.1001/jamadermatol.2015.3648 PMid:26559760

Ihn H. Eosinophilic fasciitis: From pathophysiology to treatment. Allergol Int. 2019: S1323-8930(19)30021-8. https://doi.org/10.1016/j.alit.2019.03.001 PMid:30910631

Mazori DR, Femia AN, Vleugels RA. Eosinophilic Fasciitis: an Updated Review on Diagnosis and Treatment. Curr Rheumatol Rep. 2017; 19(12):74. https://doi.org/10.1007/s11926-017-0700-6 PMid:29101481

Pinal-Fernandez I, Selva-O' Callaghan A, Grau JM. Diagnosis and classification of eosinophilic fasciitis. Autoimmun Rev. 2014; 13(4-5):379-82. https://doi.org/10.1016/j.autrev.2014.01.019 PMid:24424187

Jinnin M, Yamamoto T, Asano Y, Ishikawa O, Sato S, Takehara K, Hasegawa M, Fujimoto M, Ihn H. Diagnostic criteria, severity classification and guidelines of eosinophilic fasciitis. J Dermatol. 2018; 45(8):881-90. https://doi.org/10.1111/1346-8138.14160 PMid:29235676

Jinnin M, Ihn H, Yamane K, Asano Y, Yazawa N, Tamaki K. Serum levels of tissue inhibitor of metalloproteinase-1 and 2 in patients with eosinophilic fasciitis. Br J Dermatol. 2004; 151(2):407-12. https://doi.org/10.1111/j.1365-2133.2004.06062.x PMid:15327548

Lebeaux D, Francès C, Barete S, Wechsler B, Dubourg O, Renoux J, Maisonobe T, Benveniste O, Gatfossé M, Bourgeois P, Amoura Z, Cacoub P, Piette JC, Sène D. Eosinophilic fasciitis (Shulman disease): new insights into the therapeutic management from a series of 34 patients. Rheumatology (Oxford). 2012; 51(3):557-61. https://doi.org/10.1093/rheumatology/ker366 PMid:22120602

Kirchgessner T, Dallaudière B, Omoumi P, Malghem J, Vande Berg B, Lecouvet F, Houssiau F, Galant C, Larbi A. Eosinophilic fasciitis: typical abnormalities, variants and differential diagnosis of fasciae abnormalities using MR imaging. Diagn Interv Imaging. 2015; 96(4):341-8. https://doi.org/10.1016/j.diii.2014.06.018 PMid:25746223

Endo Y, Tamura A, Matsushima Y, Iwasaki T, Hasegawa M, Nagai Y, Ishikawa O. Eosinophilic fasciitis: report of two cases and a systematic review of the literature dealing with clinical variables that predict the outcome. Clin Rheumatol. 2007; 26(9):1445-51.https://doi.org/10.1007/s10067-006-0525-6 PMid:17345001

Tull R, Hoover WD 3rd, De Luca JF, Huang WW, Jorizzo JL. Eosinophilic fasciitis: a case series with an emphasis on therapy and induction of remission. Drugs Context. 2018; 7:212529. https://doi.org/10.7573/dic.212529 PMid:30302114 PMCid:PMC6172017

Espinoza F, Jorgensen C, Pers YM. Efficacy of Tocilizumab in the treatment of Eosinophilic fasciitis: Report of one case. Joint Bone Spine. 2015; 82(6):460-1. https://doi.org/10.1016/j.jbspin.2015.02.008 PMid:26162635

Nahhas AF, Alam M, Lim HW. Rituximab as a therapeutic consideration for refractory eosinophilic fasciitis. Int J Dermatol. 2018; 57(5):614-615. https://doi.org/10.1111/ijd.13940 PMid:29446454

Kim SR, Charos A, Damsky W, Heald P, Girardi M, King BA. Treatment of generalized deep morphea and eosinophilic fasciitis with the Janus kinase inhibitor tofacitinib. JAAD Case Rep. 2018; 4(5):443-445. https://doi.org/10.1016/j.jdcr.2017.12.003 PMid:29984277 PMCid:PMC6031588

Published
2019-05-15
How to Cite
1.
Wollina U, Hansel G, Schönlebe J, Heinig B, Temelkova I, Tchernev G, Vojvodic A, Lotti T. Eosinophilic Fasciitis – Report of Three Cases and Review of the Literature. Open Access Maced J Med Sci [Internet]. 2019May15 [cited 2020Oct.20];7(18):2964-8. Available from: https://www.id-press.eu/mjms/article/view/oamjms.2019.296

Most read articles by the same author(s)

1 2 3 4 > >>